Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 0.00 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Beigene Ltd (PK) | BEIGF | OTCMarkets | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 12.58 | 15:02:37 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 12.58 | 12.58 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0.00 | - | 11.00 - 16.78 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 12.58 | USD |
Beigene Ltd (PK) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 15.62B | 1.01B | - | 2.46B | -881.71M | -0.71 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Beigene (PK) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 5/08/2024 | 05:09 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 5/08/2024 | 05:06 | Edgar (US Regulatory) | Form 8-K - Current report |
| 3/08/2024 | 05:01 | Edgar (US Regulatory) | Form 8-K - Current report |
| 3/04/2024 | 16:22 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 2/29/2024 | 15:27 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities |
| 12/08/2023 | 05:01 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/04/2023 | 16:44 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 11/09/2023 | 15:14 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 9/21/2023 | 15:04 | Edgar (US Regulatory) | Form 8-K - Current report |
| 9/19/2023 | 05:01 | Edgar (US Regulatory) | Form 8-K - Current report |
| 7/03/2023 | 12:32 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BEIGF Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 11.28 | 12.58 | 11.00 | 12.15 | 368 | 1.30 | 11.52% |
| 6 Months | 11.28 | 12.58 | 11.00 | 12.15 | 368 | 1.30 | 11.52% |
| 1 Year | 16.78 | 16.78 | 11.00 | 14.31 | 850 | -4.20 | -25.03% |
| 3 Years | 25.3755 | 29.2541 | 11.00 | 25.98 | 42,170 | -12.80 | -50.42% |
| 5 Years | 20.1736 | 29.2541 | 11.00 | 25.94 | 39,977 | -7.59 | -37.64% |
Beigene (PK) Description
| We are a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Our internally-developed lead drug candidates are currently in late-stage clinical trials, including 21 registration or registration-enabling trials in 14 discrete cancer indications. We have submitted three new drug applications for regulatory approval in China and are planning for new drug launches and additional submissions in China and the United States in 2019 and 2020. In addition, we are marketing three in-licensed cancer drugs in China from which we have been generating product revenue since September 2017. We started as a research and development company in Beijing in 2010, focusing on developing best-in-class oncology drugs. Over the last nine years, we have developed into a fully-integrated global biotechnology company with operations in China, the United States, Europe and Australia, including a more than 800-person global clinical development team running over 50 ongoing or planned clinical trials as of January 24, 2019. We also have a growing commercial team that is selling our existing in-licensed drugs in China and preparing for launches of our internally-developed drug candidates in China and the United States, as well as internal manufacturing capabilities in China that are operational or under construction for the clinical and commercial supply of our small molecule and biologic drug candidates. |
